NCT02677103.

Trial name or title	Extracorporeal shock‐wave therapy for supraspinatus calcifying tendonitis: a randomized clinical trial comparing two different energy levels
Methods	Study design: Parallel, three‐arm, randomised controlled trial Setting: Shin Kong Wu Ho‐Su Memorial Hospital, Tapei, Taiwan Interventions: rESWT vs US‐guided needle puncture vs rESWT plus US‐guided needle puncture Analysis: not reported
Participants	Inclusion criteria: calcific tendonitis of the shoulder age 20–75 years Exclusion criteria: pregnancy clotting disorders anticoagulant or antiplatelet treatment cardiac pacemaker chronic inflammatory joint disease infections or tumours of the shoulder adhesive capsulitis hyperalgia of the shoulder due to resorption of a calcific deposit calcification of type III as defined by Gärtner or nodular or cystic type of calcification defined by Chiou
Interventions	rESWT: description of modality used: rESWT dose: an energy level of 0.26 mJ/mm², 2000 shock waves at 2 Hz frequency: once per week, for 3 weeks any additional treatment during trial: NA US‐guided needle puncture: dose: 3 mL 1% xylocaine method of administration: all needle punctures will be guided by US. The puncture needle is a 3.8 cm 22‐gauge needle attached on a 5 mL syringe. Before puncture, the skin of the puncture site will be sterilised with iodine, and the transducer will be covered with a sterilised plastic bag. After injecting 3 mL 1% xylocaine in subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back‐and‐forth puncture about 10–20 times (depending on the size of the plaques) within the calcific plaques will be performed. The needle tract will be monitored by US to make sure the needle penetrated through the calcific plaque, but does not penetrate the rotator cuff frequency: single treatment rESWT plus US‐guided needle puncture: US‐guided needle puncture, as described above, followed by rESWT, as described above
Outcomes	Outcomes included in review: pain (VAS) (6 weeks, 3 months after treatment) active ROM and passive ROM (6 weeks, 3 months after treatment) quality of life: general health status: SF–36 (6 weeks, 3 months after treatment) treatment success: participant satisfaction (6 weeks, 3 months after treatment) Outcomes excluded from review: shoulder problems (6 weeks, 3 months after treatment)
Starting date	April 2013
Contact information	Lin‐Fen Hsieh, MD, Shin Kong Wu Ho‐Su Memorial Hospital
Notes	Estimated completion date: study completed, no results posted Trial registration: ClinicalTrials.gov identifier NCT02677103. Status on 9 May 2018: recruitment completed, 61 participants enrolled, no study results available. Last update posted on 25 March 2016 on the ClinicalTrials.gov website.